Xilio Therapeutics, Inc. — Cyborg Score 6/10

Strategic Profile

Key programs include vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 antibody being studied in combination with atezolizumab, and efarindodekin alfa (XTX301), a tumor-activated IL-12 in Phase 1/2 trials. The company has approximately $137.5 million in cash as of December 31, 2025, with funding extending its anticipated cash runway into Q2 2027.

Cyborg Score Rationale

Phase 2 vilastobart data showed a 40% ORR in heavily pretreated MSS mCRC patients without liver metastases with promising response correlation to plasma TMB. However, as a clinical-stage biotech with limited approved products and significant cash burn, Xilio faces typical early-stage execution risks and market competition.

Top Insights

• Phase 2 vilastobart achieved 40% objective response rate in heavily pretreated MSS mCRC patients, demonstrating clinical validation of masked I-O approach
• Recent $40M capital raise backed by prominent investors including Gilead Sciences, OrbiMed, and Perceptive Advisors
• AbbVie collaboration ongoing with development milestone achieved for masked antibody program
• Stock trading near $0.70/share (March 2026) reflects biotech risk profile and clinical stage status

Named Competitors

• Opdivo/Yervoy — Established checkpoint inhibitors for multiple cancer indications
• Keytruda — Leading anti-PD-1 monotherapy across broad oncology portfolio
• Tecentriq — Established anti-PD-L1 platform with combination approaches

Recent Developments

• (February 2026) $40M pre-funded warrant offering closing with $137.5M total cash extending runway to Q2 2027
• (November 2025) Phase 2 vilastobart data released showing 40% ORR; efarindodekin alfa Phase 1 data showed promising tolerability
• (November 2025) Pipeline expansion with XTX501 bispecific (PD-1/masked IL-2) advancing toward planned IND mid-2026

Open the full interactive Xilio Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.